Analysis of β-Blockers Using the Agilent 1290 Infinity II LC Controlled Through Waters Empower Software

Importance of the topic

Beta-blockers are widely used pharmaceuticals for cardiovascular therapy, and robust analytical methods are essential for their quality control and research applications.
The ability to integrate high-end LC instrumentation with third-party software platforms enhances operational flexibility in analytical laboratories and ensures consistent data processing workflows.

Objectives and study overview

The primary goals of this study were to demonstrate the control of an Agilent 1290 Infinity II LC system using Waters Empower software via the Agilent Instrument Control Framework (ICF) and to evaluate the chromatographic performance in the separation of six β-blockers.
Key objectives included assessing retention time and peak area precision over multiple runs to validate system stability and reproducibility.

Methodology

A reversed-phase separation was performed on an Agilent ZORBAX Bonus-RP column (2.1 × 50 mm, 1.8 µm) using a binary gradient of 10 mM ammonium formate (pH 3) and methanol at 0.5 mL/min.
The gradient program increased from 5% to 38% organic modifier over 5 minutes, then to 80% by 6 minutes, with a total run time of 7 minutes and a post-run equilibration of 10 minutes.
Sample injections of 1 µL were cooled at 8 °C, and detection was performed with a diode array detector at 280 nm (reference 360 nm) with a data rate of 10 Hz.

Instrumentation

• Agilent 1290 Infinity II Flexible Pump (G7104A)
• Agilent 1290 Infinity II Multisampler with integrated cooler (G7167B)
• Agilent 1290 Infinity II Multicolumn Thermostat (G7116B)
• Agilent 1290 Infinity II Diode Array Detector (G7117B)
• Controlled via Waters Empower 3 (build 3471) with Agilent ICF plugin

Main results and discussion

Chromatographic separation of six β-blockers—atenolol, pindolol, labetalol, propranolol, timolol and acebutolol—was achieved within 7 minutes with baseline resolution.
An overlay of 10 consecutive runs showed excellent retention time precision (RSD < 0.1%) and peak area precision (RSD < 1.31%).
Resolution between adjacent peaks exceeded 1.5 for all compounds, ensuring reliable quantification and peak identification.

Benefits and practical applications

Integration of Agilent LC systems with Empower via ICF enables a unified control environment, reducing the need for multiple software platforms.
The demonstrated method provides high-throughput and precise quantitation of β-blockers, suitable for pharmaceutical QA/QC and related research studies.

Future trends and opportunities

Broader adoption of vendor-neutral instrument control frameworks to streamline laboratory workflows.
Extension of integrated control to advanced LC modules, mass spectrometry and multi-dimensional separations.
Application of similar strategies for clinical assays, metabolite profiling and regulatory compliance studies.

Conclusion

The study confirms that Agilent Instrument Control Framework allows full control of the 1290 Infinity II LC system within Waters Empower software, preserving all instrument functionalities.
The rapid and precise separation of β-blockers highlights the system’s performance and supports its use in high-demand analytical environments.

Reference

• Agilent Instrument Control Framework, Agilent Technologies Technical Overview, Publication Number 5990-6504EN, 2001.
• Fernandez-Pineda I., Williams R., Ortega-Laureano L., Jones R., Cardiovascular drugs in the treatment of infantile hemangioma, World Journal of Cardiology, 2016, 8(1), 74–80.